Latest News - Amgen
Top Corporates Hub
Amgen
Amgen (AMGN) Announces Retirement of CFO Peter Griffith
25.05.2026 19:54
Amgen Inc. (NASDAQ:AMGN) is one of the cheap NASDAQ stocks to buy right now. On May 19, Amgen announced the retirement of its Executive Vice President and Chief Financial Officer, Peter Griffith, who has held the role since 2020. During his tenure, Griffith was instrumental in strengthening the company’s financial position, supporting capital allocation, and […]
CFOs On the Move: Week ending May 22
22.05.2026 08:49
Amgen names a new chief financial officer, Thales hires Nissan’s former CFO and Rent the Runway’s finance chief tenders his resignation.
A Look At Amgen (AMGN) Valuation As Tavneos Safety Concerns And Withdrawal Requests Escalate
22.05.2026 06:15
Amgen (AMGN) stock is in focus after safety concerns around its rare disease therapy Tavneos, including reported patient deaths in Japan, prompted regulators and partners to restrict new prescriptions and consider withdrawal in the U.S. See our latest analysis for Amgen. At a share price of $337.42, Amgen has seen its 90 day share price return fall 9.96%, even as its 1 year total shareholder return of 27.83% and 3 year total shareholder return of 70.14% point to stronger longer term...
Amgen Inc. (AMGN): Navellier’s Long-Term Pick on Pipeline Strength and Sales Growth
21.05.2026 08:51
Amgen Inc. (NASDAQ:AMGN) is one of Louis Navellier’s top long-term stock picks. On May 14, Piper Sandler reiterated an Overweight rating on Amgen Inc. (NASDAQ:AMGN) but lowered the price target to $427 from $432. The new price target still represents significant upside potential as the research firm expects the company to deliver top-line revenue growth […]
Amgen : Statement on TAVNEOS® (avacopan)
16.05.2026 00:37
Amgen Statement on TAVNEOS® On May 15, 2026, media outlets reported 20 deaths associated with patients being treated with TAVNEOS® in Japan. The report was based on a regulatory...
Romiplate Sales Forecast and Market Size Analysis Report 2026-2034 with Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan
15.05.2026 09:19
Market opportunities for Romiplate are driven by the increasing diagnosis of immune thrombocytopenia (ITP), expansion into additional thrombocytopenia conditions, strong commercial sales, global expansion, and growing physician adoption. These factors support its anticipated growth through 2034 in major global markets.Dublin, May 15, 2026 (GLOBE NEWSWIRE) -- The "Romiplate Sales Forecast and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering. The report provides ins
How The Amgen (AMGN) Investment Story Is Shifting With New Guidance And Pipeline Updates
15.05.2026 09:13
The latest fair value estimate for Amgen has shifted slightly, from US$350.03 to US$349.66, keeping modeled upside closely aligned with prior assumptions. That small adjustment fits with recent analyst commentary, where higher and lower price targets have been clustering around the current trading range as views on growth and execution remain mixed. As you read on, you will see how to track these changing signals and what they might mean for following Amgen’s evolving story over time. Stay...
Is It Time To Reassess Amgen (AMGN) After Strong Multi Year Share Price Gains
15.05.2026 03:16
If you are wondering whether Amgen’s current share price reflects its true worth, starting with a clear look at what the market is paying for its fundamentals can help ground your view. The stock last closed at US$336.23, with returns of 2.2% over the past week, a decline of 4.2% over the past month, a 2.6% gain year to date and a 28.6% gain over the past year. The 3 year and 5 year returns sit at 64.4% and 56.2% respectively. Recent price moves sit against a backdrop of ongoing product...
3 Top Dividend Stocks to Maximize Your Retirement Income
11.05.2026 13:10
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Kennedy's health officials explored US ban of some widely used antidepressants, sources say
08.05.2026 11:53
U.S. health departmentofficials last week explored whether they could ban certaindrugs in a widely prescribed class of antidepressants as HealthSecretary Robert F. Kennedy Jr. prepared to roll out...
As AI Rewrites Drug Development, the Industry Gathers in Philadelphia to Work Out the Rules
06.05.2026 18:11
Artificial intelligence is moving faster than the frameworks designed to govern it. This June, the people responsible for closing that gap will be in one room.
Amgen’s US$300m Biologics Push And What It Means For AMGN Stock
06.05.2026 16:12
Amgen announced a $300 million expansion of its U.S. biologics manufacturing network. The plan includes a significant new investment in a Puerto Rico facility to scale next generation technologies. The move is intended to support domestic medicine production and strengthen the American supply chain. For investors tracking NasdaqGS:AMGN, this manufacturing build out adds an operational angle to a stock that is currently trading at $329.59. Over the past year, the share price return of 25.7%...
RPRX vs. AMGN: Which Stock Is the Better Value Option?
06.05.2026 15:40
RPRX vs. AMGN: Which Stock Is the Better Value Option?
Inside Amgen’s Next-Generation Labs: Powering Faster, Smarter Small Molecule Drug Discovery
06.05.2026 14:25
At a glance: $125M investment expands Amgen's South San Francisco research hub Integrated labs bring medicinal chemistry, biology, protein sciences, automation, and data science together to accelerate...
How This Amgen Rival, Up 30%, Plans To Shake Its Grip In Thyroid Eye Disease
05.05.2026 13:17
Viridian Therapeutics unveiled solid results Tuesday for its experimental eye disease treatment, a potential rival to Amgen.
What’s at stake in Amgen’s showdown with the FDA?
05.05.2026 09:09
The agency accused Amgen of manipulating data for its fast-growing drug Tavneos and wants it pulled from the market, but the large pharma is digging its heels in.
Viridian eye disease drug benefits chronic patients in late-stage trial; shares soar
05.05.2026 08:39
Viridian Therapeutics said onTuesday its experimental thyroid eye disease drug met the maingoal of a late-stage trial in chronic patients, sending itsshares up nearly 50% before the bell. ...
Amgen Is 'Aggressively Expanding' In Obesity Treatment; Here's What Investors Should Watch
01.05.2026 15:55
Amgen stock toppled Friday as investors digested its "generally in-line" first-quarter report and expansion in the obesity treatment space.
Amgen: The Quarter Where New Growth Engines Begin to Drown Out the Noise of Patent Expirations
01.05.2026 14:43
The California-based biotech giant reported solid Q1 2026 results, with revenue up to $8.62bn, from $8.15bn a year ago, with net income reaching $1.82bn. Adjusted EPS came in at $5.15, beating market...
Truist Securities Maintains Hold on Amgen, Raises Price Target to $327
01.05.2026 14:01
Truist Securities analyst Gregory Renza maintains Amgen (NASDAQ:AMGN) with a Hold and raises the price target from $325 to $327.